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Abstract: Introduction
Schizophrenia has a 1% prevalence in the population; 30% of these patients are
treatment refractory. Clozapine is the only drug licensed to treat treatment refractory
psychosis, but concerns about potential adverse effects result in only a proportion of
eligible patients being treated.  While a well documented neutropenia risk is mitigated
by routine blood testing, cardiac toxicity is a commonly cited reason to discontinue
clozapine treatment. However; there is little data on the real life cardiac outcomes in
those receiving clozapine treatment.
Methods
Retrospective review of electrocardiogram, echocardiogram and clinical outcomes in
39 inpatients with treatment-refractory schizophrenia, treated with clozapine and other
anti-psychotic medication, referred for cardiology opinion.
Results
Commonest reasons for referral were development of left ventricular (LV) impairment
or sinus tachycardia with normal LV function.  Patients were reviewed by a range of
cardiologists, receiving varied interventions.
 Median LV ejection fraction (EF) in the clozapine group was normal (52%).   Serial
echocardiograms demonstrated that clozapine treated patients with LV impairment had
no change in LVEF over a four month follow up.  LVEF did not differ between patients
treated with clozapine and other antipsychotics.  However; over an 11 year follow-up
period, 48% of patients had discontinued clozapine treatment.
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Conclusion
This naturalistic study demonstrates that clozapine is not associated with significant
cardiac mortality or morbidity.  There is a real need for multidisciplinary working
between specialist cardiologists and psychiatrists caring for these complex patients to
facilitate optimal long-term physical and mental health outcomes.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
(a) Complete manuscript title 
Hearts and minds; real life cardiotoxicity with clozapine in psychosis 
 
(b) authors' full names, highest academic degrees, and affiliations 
 
Author 1 
Dr. George Joy, MBBS MRCP(UK),  
King’s College Hospital NHS Foundation Trust 
Denmark Hill, London, SE5 9RS 
Tel: 020 3299 9000 
 
Author 2 
Mr. Eromona Whiskey, MPharm 
Clinical Lecturer, South London & Maudsley Hospital 
Denmark Hill 
SE5 8AZ 
Tel: 020 3228 6000 
 
Author 3  
Dr. Mark Bolstridge MBCHB 
South London & Maudsley Hospital 
Denmark Hill 
SE5 8AZ 
Tel: 020 3228 6000 
 
Author 4 
Dr. Alejandro Porras-Segovia, MD 
Mental Health Service 
Granada University Hospital 
Granada, Spain 
 
Author 5 
Prof. TA McDonagh BSc(HONS) MBChB (HONS) MD MRCP 
Cardiology Department, King’s College Healthcare NHS Foundation Trust 
Denmark Hill 
London 
SE5 9RS 
 
Author 6 
Dr. Carla M Plymen BSc(HONS) MCRP(UK) MD(Res) 
Cardiology Department, Imperial College Healthcare NHS Trust 
Hammersmith Hospital , Du Cane Road,  London, W12 0HS 
Tel:  020 3313 7382 
Fax: 020 3313 1684 
  
 
Author 7  
Prof. Sukhi S Shergill BSc MBBS SFHEA PhD FRCPsych 
Professor of Psychiatry & Systems Neuroscience and Honorary Consultant 
Psychiatrist 
Title Page
Institute of Psychiatry, Psychology and Neuroscience, King’s College London and 
Maudsley Hospital London 
Denmark Hill 
SE5 8AZ 
Tel: 020 3228 6000 
 
 
 (c) name and address for correspondence, including fax 
number, telephone number, and e-mail address 
Dr. George Joy 
18 Woodcroft Ave.,  
Mill Hill, 
London 
NW7 2AG 
Fax. 020 3299 3445 
Tel: 07794601143 
Email: georgejithinjoy@gmail.com 
 
(d) address for reprints  
as above 
 
(e) all sources of support, including pharmaceutical and 
industry support, that require acknowledgment and relevant 
disclosures for each author; and  
There are no sources of support to declare and no conflicts of 
interest to declare from any author 
 
(f) a running title of no more than 4 words. 
Clozapine cardiotoxicity in real-life 
 1 
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ABSTRACT 
Introduction 
Schizophrenia has a 1% prevalence in the population; 30% of these patients are treatment refractory. 
Clozapine is the only drug licensed to treat treatment refractory psychosis, but concerns about potential 
adverse effects result in only a proportion of eligible patients being treated.  While a well documented 
neutropenia risk is mitigated by routine blood testing, cardiac toxicity is a commonly cited reason to 
discontinue clozapine treatment. However; there is little data on the real life cardiac outcomes in those 
receiving clozapine treatment.  
Methods 
Retrospective review of electrocardiogram, echocardiogram and clinical outcomes in 39 inpatients with 
treatment-refractory schizophrenia, treated with clozapine and other anti-psychotic medication, referred for 
cardiology opinion. 
Results 
Commonest reasons for referral were development of left ventricular (LV) impairment or sinus tachycardia 
with normal LV function.  Patients were reviewed by a range of cardiologists, receiving varied interventions.   
 Median LV ejection fraction (EF) in the clozapine group was normal (52%).   Serial echocardiograms 
demonstrated that clozapine treated patients with LV impairment had no change in LVEF over a four month 
follow up.  LVEF did not differ between patients treated with clozapine and other antipsychotics.  However; 
over an 11 year follow-up period, 48% of patients had discontinued clozapine treatment.  
Conclusion 
This naturalistic study demonstrates that clozapine is not associated with significant cardiac mortality or 
morbidity.  There is a real need for multidisciplinary working between specialist cardiologists and psychiatrists 
Manuscript
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caring for these complex patients to facilitate optimal long-term physical and mental health outcomes. 
 
INTRODUCTION  
Clozapine is the most effective antispsychotic for treatment resistant schizophrenia, however it is significantly 
underutilised due to various cardiac side-effects, namely sinus tachycardia, myocarditis and cardiomyopathy 
[1].  Sinus tachycardia is thought to be a benign process, occurring in 25%, however; myocarditis and 
cardiomyopathy, whilst carrying a significantly lower incidence, incur significantly elevated mortality [2] [3].  
Fears surrounding such potential adverse outcomes are reflected in data which show that 30% of eligible 
patients were not being offered the clozapine whilst 57% were offered three or more different agents before 
commencing clozapine [4] [5][6].   
The BNF states that clozapine should be used with caution in those with pre-existing cardiac disease and 
should not be considered in those with severe cardiac compromise [7]: This excludes a significant proportion 
of patients, given their established cardiac risk factor burden.  Further; clozapine is frequently discontinued 
prematurely at the first sign of either cardiotoxicity or its other well-known side-effect, agranulocytosis. 
It is clear therefore, that there is considerable difficulty in commencing and maintaining therapy with 
clozapine, however, there has been no large-scale study of clozapine cardiotoxicity, nor has there been a 
prospective study of the effects of clozapine in those with established cardiac disease.   
Given that clozapine is the only evidence-based treatment licensed in refractory schizophrenia, we sought to 
review outcomes in the cohort of patients on clozapine referred for cardiac review within our academic health 
sciences centre. This ‘clozapine treated’ group was compared to a second group of patients with acute 
psychosis also referred for cardiac review but whom were taking other antipsychotic agents.   
METHODS 
We undertook a retrospective study of all patients admitted to our national mental health unit and referred, 
as inpatients, for cardiology review during the past 9 years.  This was done via a data-mining search with the 
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terms ‘schizophrenia’ ‘clozapine’, ‘antipsychotic, ‘cardiomyopathy’, ‘myocarditis’ ‘tachycardia’ on cardiology 
clinic letters collated on our electronic system.  Patient demographics were recorded, in addition to start and 
stop dates of clozapine, and dose.  Cardiac data at time of review was noted, specifically measurements of 
echocardiographic (left ventricular ejection fraction) and electrographic indices (QRS duration, QTc interval, 
heart rate) were recorded.   Mortality status (and cause of death) were obtained at time of follow up (date of 
search).    
Results were analysed using student’s t-test, Mann-Whitney U, Kruskal Wallis and one-way ANOVA’s as 
necessary.  Linear regression analysis was also undertaken to determine correlative data. 
RESULTS 
Total cohort 
During 9 years at our Institution, clozapine was started on 883 inpatients;  27 (0.3%) were referred for 
cardiology review. A further 12 inpatients on other antipsychotic agents were also referred for cardiology 
opinion.  Mean age for the total cohort was 46±13 years; 31% (12) were female; of those being treated with 
clozapine, 16 (59%) were referred specifically for tachycardia. Total follow-up time from start of the drug to 
review of clinic and cardiac data was 10.8±5.8 years. 
Clozapine treated patients – whole group 
27 patients (69% of the total) referred for review were being treated with clozapine.  Mean age at review was 
43±12 years and 33% were female (n=9; Table 1).  Median left ventricular ejection fraction (LVEF) was 52% 
(IQR 44-55) and median heart rate (HR) was 98 bpm (IQR 85-114; Table 1).   
There was no significant relationship between age and LVEF (p=0.99), age and QRS duration (p=0.16), age and 
heart rate (p= 0.73) or age and QTc interval (p=0.16).  Further, we found no significant relationship between 
time on clozapine and LVEF at review (p=0.85) or time on clozapine and QRS duration (p=0.22).  
Clozapine treatment and development of tachycardia 
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16 patients (59%) being treated with clozapine were referred to cardiology due to the development of a 
tachycardia.  This was a sinus tachycardia in all cases; no arrhythmias were documented at any time point 
during follow-up in this group.  Mean age of this cohort was 44±13 years and 5 were female.  LVEF was normal 
(55% IQR 52-59), as were all electrical intervals (Table 1 below).  Mean HR was 103bpm (IQR 94-116; Table 1).    
There was no significant relationship between time on clozapine and HR (p=0.15) or time on clozapine and QTc 
(p=0.16).  We also found no significant difference in HR in those with and without symptomatic palpitation (p= 
0.49).   
Following review by cardiology, rate controlling medication was started in 44%: Beta-blocker (n=5) and 
ivabradine (n=2).  However; there was no significant difference in HR in those whom rate controlling 
medication was started (101±10bpm) and those in whom it was not (110±14bpm; p=0.22).  40% of 
symptomatic and 45% of asymptomatic patients were treated. 
In total 17 cardiologists were involved in decisions relating to patient management (mean visits 3.75 per 
patient).  At time of follow up 4 patients (25%) had discontinued clozapine, with a time to discontinuation of 
28±31months after review. Reasons for discontinuation were neutropaenia (1), poor compliance (1), patient 
choice/refusal (2).  One patient died in this group and the cause of death was recorded as a suspected suicide.    
Clozapine ‘Cardiomyopathy’ group 
Eleven (41%) patients treated with clozapine were referred due to possible development of heart 
failure/myocarditis or cardiomyopathy. These 11 patients had a median LVEF of 38% (IQR 36-52) at first 
review; QRSd and QTc were within normal limits 90ms (IQR88-98) & 431ms (IQR416-440).  There was no 
significant relationship between time on clozapine and ejection fraction in this group (r=-0.1 p=0.78). 
Follow-up time for this group was 11.6±7 years. During this time 8 patients discontinued clozapine – five 
diagnosed with myocarditis (only one confirmed with endomyocardial biopsy) and three diagnosed with 
cardiomyopathy).  Three patients died with causes of death as (1) occlusion of descending aorta, (2) 
subarachnoid haemorrhage, and (3) intestinal pseudo-obstruction (latter two patients were still on clozapine 
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at time of death).  18 different cardiologists were involved in the management of this patient group; cardiac 
medication used included: 82% bisoprolol (9), 82% ace inhibitor (9), 27% mineralocorticoid receptor 
antagonist (3).  
Clozapine Group Comparison  
There was no significant difference in age (p=0.49), gender, QRS duration (p=0.74) or QTc interval (p=0.56) in 
those developing a tachycardia or symptoms and signs of heart failure. LVEF was significantly lower in the 
clozapine ‘cardiomyopathy’ group (38% vs 55%; p<0.001) and HR was significantly higher in the clozapine 
tachycardia group (103 vs 83bpm; p=0.002).   
Those with LV impairment tended to be seen earlier than those who developed tachycardia, however; this did 
not reach statistical significance with a median time to review of 4.7 vs 7.2 years (p=0.24). Patients in the 
former group were far more likely to have clozapine discontinued compared to those in the tachycardia group 
(p=0.027) and clozapine tended to be discontinued sooner after referral in the clozapine cardiomyopathy 
group compared to the clozapine tachycardia group (median time 0.3 vs 2.3 years p=0.065). 
 
Non-clozapine antipsychotic treatment  
Twelve patients being treated with an antipsychotic other than clozapine were referred for review during the 
same time period (Table 2).  Average age was 56±9 years and 25% (3) were female.  Median HR was 75bpm 
(IQR67-96); QRS duration 95ms (IQR 90-117); QTc interval 451ms (IQR90-117) and LVEF 31% (IQR 27-43).   
This cohort was treated with antipsychotic medication for 4.2 (1.6-9.7) years until initial cardiology review.  At 
follow-up, only 8 were being treated with the same antipsychotic; 4 had discontinued their original 
antipsychotic.  Only one of these was secondary to a suspected cardiac side-effect (risperidone); the 
remainder comprised risperidone (n=2)  and olanzapine (n=1) and these agents were changed for non-cardiac 
reasons.  One patient died in this group with cause of death recorded as heart failure (this patient was on 
risperidone).  
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All patients with reduced LVEF were treated with at least 2 prognostic heart failure medications: Diagnoses 
comprised ischaemic cardiomyopathy (n=4), dilated cardiomyopathy (DCM) secondary to hypertension (n=3), 
DCM secondary to valvular disease (n=2), DCM related to chemotherapy (n=1) and DCM possibly viral cause 
(n=1).  Sixteen cardiologists managed this group of patients. 
Comparison Clozapine vs other antipsychotics: Reduced LVEF 
There was a significant difference in age at cardiology review with those on clozapine being younger than 
those not taking this drug (44±13 vs 56±9 years; p=0.02). There was no significant difference between length 
of time on drug at review between the two groups (p=0.35). There was otherwise no significant differences in 
LVEF, HR, QRS duration or QTc interval between the two groups .   
Serial Echocardiogram data in the clozapine cardiomyopathy group and non-clozapine antipsychotics 
In total, 7 patients in both groups (14) had serial echocardiograms during their drug treatment.  Patients on 
non-clozapine antipsychotics had echocardiograms over a longer duration of time (28±25 months vs 4±3 
months; p=0.029) compared to those on clozapine.  
There was a non-significant trend towards clozapine having less deterioration in LVEF per month compared to 
other antipsychotics (0.8±1.4% vs 0.3±0.8%; p= 0.09).  Patients on non-clozapine antipsychotics were more 
likely to experience deterioration in ejection fraction during treatment 86% vs 14% p=0.004.  In the 4 patients 
on clozapine that did have an echocardiogram before treatment, we find a mild mean LV impairment (513%) 
which did not significantly deteriorate post-clozapine treatment (mean 544%; p=0.18). 
DISCUSSION 
Clozapine has been shown to reduce all-cause mortality, homelessness and suicidality in treatment resistant 
schizophrenia, as compared to other antipsychotics, however anxiety regarding cardiotoxicity significantly 
limits its use [8].  Our experience appears to contradict many of the concerns regarding its use; this study 
shows that clozapine is generally very safe, with an absence of any cardiac related mortality during the follow 
up period, and no evidence that longer duration of treatment correlated with deterioration in cardiac 
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function, even in those with preceding LV impairment.   Despite this, we also show that our cohort had a 
significant number of patients where clozapine was discontinued.    
Our findings confirm that the cardiotoxic effects related to clozapine tend to fall into two distinct categories: a 
sinus tachycardia with preserved left ventricular function, and a presentation with impairment of left 
ventricular function without significant tachycardia.  It’s heartening that none of those in the tachycardia 
group developed cardiac disease during the follow up period.  Two patients in this group had borderline 
impaired ejection fraction at review; one had undergone previous cardiothoracic surgery to repair a flail mitral 
valve leaflet, and the other had suspected ischaemic cardiomyopathy.  Neither showed progression of LV 
impairment and no other patient in this group developed this.  Our findings would therefore support the 
literature that clozapine associated tachycardia is benign, however further prospective study is needed to 
assess the long-term benefits of masking tachycardia with rate-controlling drugs. 
Tachycardia is also a recognized feature, albeit extremely non-specific, of myocarditis.  We found that 59% of 
referrals to the cardiology service with ‘tachycardia’ were prompted due to a concern of myocarditis in the 
patient.   Our study estimates an average incidence of clozapine myocarditis at 0.11%, less than current 
estimates of the incidence (0.7-1.2%) [9]. The only definitive method for diagnosis myocarditis is through 
endomyocardial biopsy, which was only undertaken in one of our patients in the study.  The clinical features of 
myocarditis are wide-ranging and non-specific, however tachycardia does not feature in its diagnostic criteria, 
and often complicates the initial dose titration of the drug.  Ronaldson et al advocated for weekly CRP & 
troponin monitoring in the first month of starting clozapine. CRP and troponin are both sensitive but non-
specific for myocarditis and would be excellent gatekeepers to echocardiography, especially in the first month 
of dose-titration where myocarditis is most common, however the usefulness of this screening method has 
not been assessed and does not form part of standard practice [10][11].   
We find no significant correlation between duration on clozapine and left ventricular EF suggesting that 
clozapine does not cause a cumulative detrimental effect on cardiac function as supported by another study 
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by Chow et al as outlined below [12].  In those patients with LV systolic dysfunction already present at the 
time of cardiology review, we found no deterioration in cardiac function in the short term whilst remaining on 
clozapine.  Baseline echocardiography is not routinely performed in our patients prior to starting clozapine, 
thus it is difficult to be sure if LV systolic dysfunction pre-dated - and was thus unrelated to - clozapine use: We 
should remember that this cohort of patients is at significant risk for other cardiovascular disease. 
Other studies might suggest that long-term clozapine use is associated with a small decline in LV systolic 
function over time.   Chow et al compared patients with schizophrenia receiving either clozapine (n=100) or 
taking non-clozapine antispychotics (n=21) and 20 healthy, untreated, individuals over a 2 year period.  They 
noted a reduced EF of approximately 3.9% in the clozapine group compared with the group taking other 
antispsychotics , and 6.5% compared to the healthy group [12].  We feel that comparing those with 
schizophrenia and its incumbent cardiovascular risk profile to healthy individuals is fundamentally flawed and, 
further; a 4% difference between the groups is well within the established margin of reporting error for LVEF.  
Another group studied 38 patients on clozapine over a 12 month period and likewise found subclinical LV 
dysfunction in one third of treated patients with a 5% decline in EF during the course of the study [13].  The 
authors in this latter group however, ascribe LV dysfunction to an EF of between 50-55%: many cardiologists 
would feel this is within the normal range and as such it is difficult to interpret the findings of this study.  It is 
also very important to note the major limitation in these studies is that the use of prognostic heart failure 
medications were not described in the treatment or control groups; this would significantly affect LV function, 
but also change and recovery of such also [12, 13]. 
Other retrospective studies namely conducted by Ronaldson et al and Haas et al describes clinical features, 
biochemical and echo findings of patients diagnosed with clozapine myocarditis. [1][3]  Our study is unique in 
that provides additional insight into the management approaches adopted by clinicians, and a comparison 
with cardiac outcomes of non-clozapine antipsychotics, something that has not yet been described to our 
knowledge.  Our study also has the longest follow-up period for these patients at 11 years and data was 
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obtained from the largest psychiatric research centre in Europe.      
Our experience is that the short to medium term outcome during therapy with clozapine is acceptable with no 
observable deterioration in LV function.  Any potential decline in cardiac function with clozapine needs to be 
balanced against the beneficial effects of the drug on patients with treatment-resistant schizophrenia, which 
carries its own considerable morbidity and mortality.  Effective prognostic medical therapy of LV dysfunction 
would be hoped to support the ongoing use of clozapine:  This is something that facilitates ongoing cancer 
therapy with a similar agent that causes LV dysfunction, trastuzamab [14].  For this reason, the authors 
advocate for referral and ongoing follow-up of these patients in specialist heart failure units.   
During the 9 years data was collected, 883 patients in total were started on clozapine in our Trust, 
approximating to 100 initations per year.  Despite this volume, there are no national clinical guidelines for the 
monitoring of cardiotoxicity in patients receiving clozapine; a starting point might be adopting those already in 
place for anti-cancer drugs; such as the afore-mentioned trastuzamab, used in breast cancer.  Here, baseline 
echocardiograms are done followed by further studies at 4 and 8 months and on completion of treatment 
[14].   
Our study found 18 different cardiologists involved in the management of these patients, with wide ranging 
clinical decisions based on the preference and expertise of the individual cardiologist, the vast majority of 
whom were not heart failure specialists.  There is a wealth of data to support the fact that any patient with LV 
dysfunction has less mortality under a specialist [15] and as such we propose that a dedicated team (including 
a heart failure specialist) should manage these patients facilitating early review and ongoing dialogue with 
psychiatrists to enable continuation of clozapine and prevention of premature (unnecessary) discontinuation 
of it.  Of the significant number of patients who had clozapine discontinued, it is entirely possible that some of 
might have been advised to continue had their care been under specialist joint supervision and had there been 
structured guidelines in place.  The lack of a cohesive coordinated approach to care in our study is emphasized 
by the finding that the group of patients receiving heart rate control drugs compared to those that did not had 
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no significant difference in heart rate nor symptoms nor outcome. 
Tendency to increased cardiac mortality in patients with schizophrenia is attributable at least in part to the 
adverse metabolic effects of antipsychotics, including weight gain, dyslipidaemia and diabetes [16].  However, 
one of the largest population studies to date, the Fin11 trial, demonstrates that clozapine reduces all-cause 
mortality as compared to other anti-psychotics [8]. Of course, the better treated their mental health is the 
better treated the cardiac problems tend to be.   The majority of antipscyhotics in common use have been 
associated with cardiotoxicity to varying degrees as described by Coulter et al, with the highest incidence 
attributed to clozapine use [17].  However a bias must be conferred to the fact that clozapine cardiotoxicity is 
much better described that cardiotoxicity associated with other antipsychotics .  This bias is observed in our 
cohort of patients on non-clozapine antipsychotics where only one patient had cardiac side-effect mentioned 
as a contributing factor to their impaired cardiac function, in contrast to clozapine where this was considered 
the culprit in all patients, despite very similar cardiac risk factor profiles.  
Conclusions: 
Clozapine use is relatively safe with very acceptable short and medium term data.  Misconceptions and lack of 
specialist knowledge drive early termination of its use and fears regarding what are often benign side effects. 
We advocate for the promotion of joint working between heart failure and psychiatric teams in 
multidisciplinary fashion.  
Limitations 
Although we are the largest mental health unit in the UK, the sample size presented here is relatively small.  It 
is possible that this reflects the low, but true, incidence of clozapine cardiotoxicity however it is also possible 
that patients may have been missed due to referral to the emergency department instead of cardiology 
specifically.  This is unlikely however, as such patients would be expected to have been subsequently picked 
up by the cardiologists.  It is also possible that sub-acute incidences of myocarditis were missed – however we 
feel that this reflects the nature of myocarditis in that many healthy individuals will never present to medical 
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services either.  In our unit we undertake CRP and troponin measurements on starting clozapine so it is 
unlikely that even subacute cases were missed however.   
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Table 1: Demographics, cardiac variables and p-values.  *denotes comparison between the clozapine cardiomyopathy 
and tachycardia groups. **denotes comparison between clozapine cardiomyopathy and other antipsychotics group 
 
 
 
 Other   
Antipsychotics group 
(n=12) 
Clozapine 
‘Cardiomyopathy’ group 
(n=11) 
Clozapine 
‘Tachycardia’ group 
(n=16) 
Clozapine 
Total group  
(n=27) 
 
p value* 
Whole group 
(n=39) 
Age, years 56 9 (p=0.02)** 44 ± 13 40 ± 13 43 ± 12 0.49 46+/-13 
Gender (% female) 3 (25%) 4 (36%) 5 (31%) 9 (33%) -/- 12 (31%) 
Time on drug at 
review, median 
(IQR) years 
4.2 (1.6-9.7)  p=0.35** 4.7 (0.3-7.3) 7.2 (1.3-10) 4.8 (0.8-8.5) 0.24 4.8 (0.8-8.5) 
Heart rate  
Median (IQR) bpm 
75 (67-96) p= 0.63** 83 (76-90) 103 (94-116) 98 (85-114) 0.002* 92 (79-106) 
QRS duration  
Median (IQR) ms 
95 (90-117) p=0.09** 90 (88-98) 90 (85-96) 90 (86-96) 0.74 90 (88-99) 
QTc interval  
Median (IQR) ms 
451 (422-502) p = 
0.14** 
431 (416-440) 432 (418-453) 434 (418-458) 0.56 437 (418-460) 
LVEF  
Median (IQR) % 
31 (27-43) p=0.26** 38 (36-52) 55 (52-59) 52 (44-55) <0.001* 46 (36-55) 
Clozapine 
discontinued 
- 8 (73%) 4 (25%) 13 (48%) 0.027*  
